Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EPS (Weighted Average and Diluted) (2017 - 2025)

OptimizeRx's EPS (Weighted Average and Diluted) history spans 15 years, with the latest figure at $0.04 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 108.0% year-over-year to $0.04; the TTM value through Sep 2025 reached $0.25, up 118.52%, while the annual FY2024 figure was -$1.1, 6.8% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was $0.04 at OptimizeRx, down from $0.08 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.26 in Q4 2024 and bottomed at -$0.5 in Q3 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.18 (2023), against an average of -$0.13.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 2000.0% in 2022 before it skyrocketed 207.46% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.03 in 2021, then plummeted by 200.0% to -$0.03 in 2022, then plummeted by 700.0% to -$0.24 in 2023, then skyrocketed by 207.46% to $0.26 in 2024, then plummeted by 84.49% to $0.04 in 2025.
  • Per Business Quant, the three most recent readings for OPRX's EPS (Weighted Average and Diluted) are $0.04 (Q3 2025), $0.08 (Q2 2025), and -$0.12 (Q1 2025).